68Ga-labeled NY104 PET Imaging in Patients

Launched by AFFILIATED HOSPITAL OF JIANGNAN UNIVERSITY · Nov 27, 2022

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients voluntarily signed informed consent;
• • 2. Age 18-75, male or female;
• • 3. Patients diagnosed with renal cell carcinoma confirmed by histopathology or cytology;
• • 4. At least one measurable solid lesion has been examined according RECIST1.1 standard;
• • 5. ECOG score 0\~3; Life expectancy of at least 3 months;
• Exclusion Criteria:
• • 1. Recovery from major trauma (including surgery) within 4 weeks prior to study treatment;
• • 2. Patients with systemic or locally severe infections, or other serious coexisting diseases;
• • 3. Patients with abnormal immune function or who have recently used immunosuppressive or potentiating agents including various vaccines;
• • 4. Patients with autoimmune diseases, including rheumatoid arthritis;
• • 5. Inadequate control of arrhythmias, including atrial fibrillation;
• • 6. Uncontrolled hypertension;
• • 7. Patients with allergies or allergies to any component of the imaging agent or antibody;
• • 8. Patients who cannot undergo PET/CT imaging scan;
• • 9. Syphilis, HBV, HCV, or HIV positive subjects;
• • 10. Male and female subjects of reproductive age cannot take effective contraceptive measures;
• • 11. Pregnant or lactating women;
• • 12. Patients with a history of mental illness or related conditions;
• • 13. Other subjects considered unsuitable by researchers.